Caraway, AbbVie Ink Deal to Develop TMEM175-targeting Therapies

Caraway, AbbVie Ink Deal to Develop TMEM175-targeting Therapies

296553

Caraway, AbbVie Ink Deal to Develop TMEM175-targeting Therapies

Caraway Therapeutics is partnering with AbbVie to develop and market Caraway’s small molecule therapies targeting TMEM175, a potassium ion channel implicated in Parkinson’s disease and other neurodegenerative disorders. TMEM175 is present in lysosomes — tiny compartments in cells containing enzymes that break down unwanted cell parts, digesting and recycling different types of molecules. When lysosomes don’t work properly, waste accumulates inside cells instead of being degraded and cleared. Rare genetic variations in the TMEM175 gene, which provides…

You must be logged in to read/download the full post.